ELV

Business profile & competitive position

Elevance Health Inc. (NYSE: ELV) sits in the Healthcare sector and is classified under the Medical – Healthcare Plans industry. In plain terms, it is one of the largest U.S. health insurers, serving approximately 45.2 million medical members through affiliated health plans as of December 31, 2025. The company offers network-based managed care risk-based plans to the Individual, Employer Group, Medicaid and Medicare markets, and also sells fee-based managed care services to self-funded employers and other customers. Revenue also comes from pharmacy and health service fees through its Carelon businesses.

Operationally, Elevance Health is an independent Blue Cross and Blue Shield Association licensee, operating as the Blue Cross and/or Blue Shield licensee in 14 states and territories under names such as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. It reports through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. This structure means ELV is more than a traditional insurer—it is an integrated platform combining medical benefits, pharmacy benefit services and care-management capabilities.

The competitive implications from the financial data are stark: a 2.5% net margin is thin, but an 11.2% return on equity shows the company can still generate reasonable shareholder returns through scale, capital turnover and float management. In managed care, razor-thin margins are standard; the real moat is membership breadth, provider-network density and brand trust. ELV’s 45.2 million members and its Blue Cross/Blue Shield licensing footprint support that scale argument, but the low margin also means small shifts in medical loss ratios or reimbursement rates can materially affect profitability.

Financial posture

Elevance Health currently carries an $85.1 billion market capitalization and trades at a P/E ratio of 17.4. The stock has a beta of 0.69, suggesting it tends to be less volatile than the broader equity market, which is consistent with healthcare plans acting as defensive, service-based businesses. Profitability metrics include a 2.5% net margin and an 11.2% ROE. At the most recent snapshot, the price was $392.37 and the 50-day EMA was $391.96, while RSI registered 47.8.

A P/E of 17.4 is neither deeply discounted nor aggressively expensive on its face, but it must be judged against the 2.5% net margin. Managed-care companies rarely sport wide net margins; pricing power is constrained by regulation, contract renewals and government reimbursement schedules. The ROE figure is the more encouraging signal—double-digit returns on equity amid a high-volume, low-margin model imply the balance sheet and capital allocation are supporting shareholder value, not just top-line scale.

Strategic priorities & outlook

Elevance Health’s most recent SEC 10-K filing outlines a clear operational agenda. The company aims to continue promoting value-based payment models that align incentives to deliver care in the right setting at the right time. It also plans to rationalize its portfolio of businesses and products, aligning investments to optimize core franchises, invest in higher-growth opportunities and accelerate value creation through expanded capabilities and services.

Technology and customer interaction are a second pillar. Elevance says it intends to enhance interactions with customers, care providers, brokers, agents and employees through technological solutions and advanced tools that support distribution, service, clinical coordination and administrative efficiency. Management also emphasizes the need to maintain market-competitive value while achieving “appropriate profitability” across customer segments.

One notable fact anchors the financial profile: U.S. government agencies accounted for approximately 32% of total consolidated revenues in 2025, with the majority reported in the Health Benefits segment. That concentration ties a meaningful portion of revenue to Medicare, Medicaid and other government-funded programs, making reimbursement policy a first-order variable in any forward-looking assessment.

Macro & geopolitical exposure

As a Healthcare Plans company, Elevance Health is exposed primarily to regulatory and reimbursement risk rather than commodity prices or direct foreign-trade dynamics. Federal and state policies governing Medicare Advantage rates, Medicaid expansion, Affordable Care Act marketplace rules and employer-sponsored coverage are the macro levers that matter most. Changes in reimbursement rates, minimum medical loss ratio requirements or eligibility rules can swing revenue and margin quickly.

The CarelonRx segment adds pharmacy-benefit-manager exposure, which means drug-pricing regulation, rebate reform and generic-drug supply dynamics are also relevant. Because roughly 32% of revenue comes from U.S. government agencies, federal budget debates, debt-ceiling uncertainty or changes in administration priorities are macro considerations. Currency and traditional supply-chain disruption are less central for a domestically oriented health insurer, but healthcare labor costs and provider-network negotiations are local supply-side factors.

Recent developments

Recent news has centered on institutional positioning and relative valuation. On August 31, 2026, defenseworld.net reported that Beaconlight Capital LLC had taken a new position in Elevance Health. Two days earlier, on August 24, 2026, the same publication noted that Barrow Hanley Mewhinney & Strauss LLC had established a $175.05 million position.

On August 25, 2026, two competing narratives appeared. Zacks.com published a “UnitedHealth vs. Elevance” managed-care comparison, framing the stocks as rival picks in the sector. The same day, gurufocus.com carried a DCF-based valuation headline asserting that ELV could be worth $614. These stories highlight active institutional interest and a debate about whether the stock is undervalued, but they are analytical opinions rather than confirmed outcomes.

Earnings behavior & post-earnings drift

Elevance Health has a solid recent earnings record: over the last eight reported quarters, it beat estimates six times, for a 75% beat rate, with an average surprise of 7.2%. Across those quarters, the average five-day post-earnings price move has been 2.78% to the upside. That sounds like a reliable positive drift, but the last four quarters reveal a more complicated picture.

On July 15, 2026, ELV reported $7.45 EPS against a $6.21 estimate, a 20.0% beat. The stock fell 4.48% the next day and drifted down 0.32% over the following five days. On April 22, 2026, the company delivered $12.58 versus $10.82, a 16.3% beat, and the stock surged 5.51% the next session and 14.76% over the next five days. January 28, 2026 produced $3.33 versus $3.10, a 7.4% beat, with a modest 1.5% next-day gain but a five-day decline of 0.37%. October 21, 2025 showed $6.03 versus $4.93, a 22.3% beat, yet the stock fell 1.3% the next day and 2.96% over the following week.

The pattern is useful for traders and analysts: a beat is not a guarantee of a post-earnings pop, let alone a sustained upward move. The average +2.78% five-day drift is driven mostly by the April 2026 outlier; absent that quarter, the recent drift would look far flatter. Forward-looking, Elevance Health is scheduled to report again on October 21, 2026 before the market open, with a current consensus EPS estimate of $4.66.

For a deeper dive into how institutional analysts currently view Elevance Health across valuation, forecast revisions and consensus expectations, review the full institutional verdict rather than relying on any single headline or earnings outcome.